23andMe makes $400m telehealth play, gulping down Lemonaid
pharmaphorum
OCTOBER 25, 2021
The company is best known for its saliva-based health and ancestry DNA testing targeted at consumers, but also uses its genetic database to look for new targets for drug development. The transaction is expected to close before the end of the year. The post 23andMe makes $400m telehealth play, gulping down Lemonaid appeared first on.
Let's personalize your content